
Samsung Bioepis and Celltrion Set for Showdown in Korea’s Osteoporosis Drug Market
Samsung Bioepis and Celltrion Pharm are going head‑to‑head in South Korea’s osteoporosis treatment market after partnering with Hanmi Pharmaceutical and Daewoong Pharmaceutical, respectively. Both companies have listed their biosimilar versions of Amgen’s …